Saturday, October 3, 2026

EUR/CHF Slides By 1% In The Last 10 Sessions

ViaNews Editorial Team

September 4, 2024

EUR/CHF Slides By 1% In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.09% for the last 10 sessions. At 20:06 EST on Tuesday, 3 September, EUR/CHF (EURCHF) is $0.94.

EUR/CHF's yearly highs and lows, it's 3.976% up from its 52-week low and 5.448% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • According to FXStreet on Monday, 2 September, "However, two-year EUR:USD interest rate swap differentials are still trading inside of 100bp and support EUR/USD trading around 1.10/1.11. ", "If not, the case builds further that EUR/USD remains a 1.05-1.11 story until further notice."
  • Eur/usd finds floor to arrest pullback, but downside pressures remain. According to FXStreet on Monday, 2 September, "Despite holding deep in bull country, EUR/USD is still facing a steepening bearish pullback as shorts congregate targets just above the 50-day EMA at 1.0956."
  • According to FXStreet on Tuesday, 3 September, "For now, those like us seeing EUR/USD holding above 1.10 will be happy with some support ahead of key US data later this week. "
  • According to FXStreet on Tuesday, 3 September, "We think there is more to come here plus EUR/USD showed some reversal limiting the negative impact from the previous days. "

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com